ELAN Stock Recent News
ELAN LATEST HEADLINES
ELAN Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO, CA / ACCESSWIRE / October 18, 2024 / Elanco Animal Health (NYSE:ELAN) is facing a securities class action lawsuit alleging the company misled investors about the safety and regulatory path of its new dermatology drug, Zenrelia. Hagens Berman urges Elanco investors who suffered substantial losses to submit your losses now.
NEW YORK, NY / ACCESSWIRE / October 17, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated.
NEW YORK , Oct. 17, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Elanco Animal Health Incorporated ("Elanco" or the "Company") (NYSE: ELAN) and certain officers. The class action, filed in the United States District Court for the District Of Maryland, and docketed under 24-cv-02912 is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Elanco securities between November 7, 2023 and June 26, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Elanco Animal Health (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
SAN FRANCISCO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Elanco Animal Health (NYSE: ELAN) is facing a securities class action lawsuit alleging the company misled investors about the safety and regulatory path of its new dermatology drug, Zenrelia.
LOS ANGELES, CA / ACCESSWIRE / October 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company 's securities between November 7, 2023 and June 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before December 6, 2024.
NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated.
NEW YORK , Oct. 17, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN). Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
NEW YORK, NY / ACCESSWIRE / October 16, 2024 / If you suffered a loss on your Elanco Animal Health Incorporated (NYSE:ELAN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/elanco-animal-health-incorporated-lawsuit-submission-form?prid=108799&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / October 16, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated.